The Cancer Letter

Inside information on cancer research and drug development

Drugs & Targets

C2i Genomics launches C2inform MRD test for distributed cancer monitoring in Europe

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

C2i Genomics launched its C2inform minimal residual disease test across Europe after obtaining CE-IVD marking in the EU, UK, and Switzerland. The company also announced the completion of several clinical trials. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account